Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Odevixibat (A4250) is an effective, selective and orally active ileal bile acid transporter inhibitor. Odevixibat has the potential for the treatment of primary biliary cirrhosis. Odevixibat reduces cholestatic liver and bile duct injury in mice model.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | 35 days | $ 78.00 | |
5 mg | 35 days | $ 375.00 | |
10 mg | 35 days | $ 670.00 | |
25 mg | 35 days | $ 1,180.00 |
Description | Odevixibat (A4250) is an effective, selective and orally active ileal bile acid transporter inhibitor. Odevixibat has the potential for the treatment of primary biliary cirrhosis. Odevixibat reduces cholestatic liver and bile duct injury in mice model. |
In vivo | Odevixibat obviously decreases bile flow and biliary BA output, which correlates with reduced bsep transcription, while Ntcp and Cyp7a1 are induced. Odevixibat (0.01% (w/w) in chow diet; 4 weeks) improves sclerosing cholangitis and significantly decreases serum alanine aminotransferase, alkaline phosphatase and BAs levels, hepatic expression of pro-inflammatory and pro-fibrogenic genes and bile duct proliferation in Mdr2-/- mice [1]. |
Synonyms | A4250 |
Molecular Weight | 740.93 |
Formula | C37H48N4O8S2 |
CAS No. | 501692-44-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 150.0 mg/mL (202.5 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Odevixibat 501692-44-0 Others A4250 A-4250 A 4250 inhibitor inhibit